Companies / BOT

BOTANIX PHARMACEUTICALS LTD

ASX:BOTPharmaceuticals, Biotechnology & Life Sciences
2.73B shares on issueASX (delayed) · as of 28 July 2026$0.021price · delayed$62.9Mmarket cap · indicative
D
Dilution grade

Share count grew 51% in 24 months; runway 2–4 quarters; options/rights overhang 35% of shares

Cash runway3.1 quarters of funding
Share-count growth (24m)51.2%
Raise cadence (24m)2 cash raises
Options & rights overhang35.3% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

BOTANIX PHARMACEUTICALS LTD's ordinary share count increased 51.2% between June 2024 and May 2026 to 2.73B shares. The company raised capital twice in that period for total disclosed proceeds of A$85.0M, most recently A$45.0M in February 2026. Options and rights on issue could convert into 966M new shares, equal to 35.3% of the current share count, with the nearest expiry in August 2026 and 0% currently in the money. At the June 2026 quarter the company reported A$33.3M in available cash, representing 3.1 quarters of cover at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
35.3%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
3.1 qtrs
Cash cover · 2–4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 2.73B per ASX (delayed) (28 July 2026).
2.01B2.28B2.54BDec 24Sept 25July 26Cash raise · 12 Feb 2026Cash raise · 11 Apr 2025

Cash runway

3.1 qtrs
Two to four quarters of funding at the recent spend rate.
$33.3M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
25 May 20262A · quoted issueBOT : ORDINARY FULLY PAID2.73BAppendix 2A
21 May 20263H · cancellationBOT : ORDINARY FULLY PAID2.72BAppendix 3H
13 May 20262A · quoted issueBOT : ORDINARY FULLY PAID2.72BAppendix 2A
19 Apr 20262A · quoted issueBOT : ORDINARY FULLY PAID2.72BAppendix 2A
19 Apr 20263G · unquotedBOT : ORDINARY FULLY PAID2.64BAppendix 3G
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

2 cash raises in the last 24 months · 1 in the last 12 months

$45.0M
Capital raise
12 Feb 2026
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

35.3%
Total overhang · of current shares
0.0%
In the money · at current price
966.0M
Potential new shares
Aug 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
20 Apr 2026Stewart WasherOther655k5.0M—3Y notice
20 Apr 2026Daniel SharpOther2.1M4.0M—3Y notice
20 Apr 2026Dr Patricia WalkerOther1.7M——3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

26 July 2026Botanix Q4 FY26 Investor Update Webinar Presentation
26 July 2026$PBotanix Quarterly Activities Report and Appendix 4C Q4 FY26
19 July 2026Botanix Webinar on 27 July - Registration Information
12 July 2026$PNotice of Allowance for US patent on Sofdra drug substance
6 July 2026$PIntention to Grant a European patent on Sofdra applicator
25 May 2026Application for quotation of securities - BOT
21 May 2026Notification of cessation of securities - BOT
13 May 2026Application for quotation of securities - BOT
8 May 2026Securities Trading Policy
6 May 2026Botanix announces change of address
3 May 2026Botanix appoints Chief Operating Officer
28 Apr 2026Botanix Q3 FY26 Investor Update Webinar Presentation
28 Apr 2026$PBotanix Quarterly Activities Report and Appendix 4C Q3 FY26
24 Apr 2026Change of Director's Interest Notice x5
20 Apr 2026Botanix Webinar - 29 April - Registration Information
19 Apr 2026Notification regarding unquoted securities - BOT
19 Apr 2026Application for quotation of securities - BOT
16 Apr 2026Change of Director's Interest Notice x5
16 Apr 2026Completion of Security Purchase Plan
16 Apr 2026Notification of cessation of securities - BOT

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.